Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIXPNG)

Drug Name
CHR-3996 Drug Info
Synonyms CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
49857317
CAS Number
CAS 1256448-47-1
TTD Drug ID
DMIXPNG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase 3 (HDAC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [4]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [4]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [4]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [4]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [4]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [4]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [4]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [4]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [4]
PMID29671355-Compound-8 DM7YQJK N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 2 (HDAC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [4]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [4]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [4]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [4]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [4]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [4]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [4]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [4]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [4]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [4]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [5]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [6]
Panobinostat DM58WKG Chronic graft versus host disease Approved [5]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [7]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [8]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [9]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [10]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [11]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [5]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [3]
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [3]
Histone deacetylase 3 (HDAC3) TT4YWTO HDAC3_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT03397706) Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies. U.S. National Institutes of Health.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8391).
3 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
4 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
5 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
9 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
12 2011 Pipeline of 4SC AG.